Clinical Effectiveness of Topical Cyclosporine A 0.05% After Laser Epithelial Keratomileusis

Lee, Hyo Seok; Jang, Jae Yong; Lee, Seung Hyun; Im, Seong Kyu; Yoon, Kyung Chul

doi:10.1097/ico.0b013e31829100e5

Cited by 9 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…39,61 As mentioned above, various anti-inflammatory drugs, such as topical steroids and cyclosporine, have been widely used to treat DED, and studies have shown that anti-inflammatory treatment has a beneficial effect on tear secretion, tear film stability, and ocular surface integrity. 62,63 In addition, as oxidative stress has a potent role in the pathogenesis of DED, antioxidative treatment has shown therapeutic effects against DED, proven by the improvement in various ocular surface parameters. 61 Therefore, we further investigated the effects of CJ extract on various clinical parameters, including tear volume, tear film BUT, and corneal fluorescein staining in a mouse model of EDE.…”

Section: Discussionmentioning

confidence: 99%

Anti-Inflammatory and Antioxidative Effects of Camellia japonica on Human Corneal Epithelial Cells and Experimental Dry Eye: In Vivo and In Vitro Study

Lee

Choi

Cui

et al. 2017

Invest. Ophthalmol. Vis. Sci.

Self Cite

View full text Add to dashboard Cite

Citation: Lee HS, Choi J-H, Cui L, et al. Anti-inflammatory and antioxidative effects of Camellia japonica on human corneal epithelial cells and experimental dry eye: in vivo and in vitro study. Invest Ophthalmol Vis Sci. 2017;58:119658: -120758: . DOI:10.1167 PURPOSE. To analyze the anti-inflammatory and antioxidative effects of Camellia japonica (CJ) on human corneal epithelial (HCE) cells and its therapeutic effects in a mouse model of experimental dry eye (EDE). METHODS.Camellia japonica extracts of varying concentrations (0.001%, 0.01%, and 0.1%) were used to treat HCE cells. Dichlorofluorescein diacetate (DCF-DA) and dihydroethidium (DHE) assays were performed. The production of peroxiredoxin (PRX) 1-6 and manganesedependent superoxide dismutase (MnSOD) in HCE cells was assessed using Western blot analysis. Furthermore, eye drops containing 0.001%, 0.01%, or 0.1% CJ extract or a balanced salt solution (BSS) were applied to the EDE. Clinical parameters were measured 7 days after treatment. The levels of inflammatory markers and intracellular reactive oxygen species (ROS) were measured.RESULTS. Treatment with 0.01% and 0.1% CJ extracts decreased apoptosis in HCE cells. In addition, band intensities of PRX 1, 4, and 5, as well as MnSOD, after hydrogen peroxide (H 2 O 2 ) treatment showed a significant improvement after pretreatment with 0.01% and 0.1% CJ extracts. Mice treated with 0.1% CJ extract showed significantly improved clinical parameters when compared to those of the EDE control and BSS groups. A significant decrease in the levels of inflammatory markers and intracellular ROS was observed in the 0.01% and 0.1% CJ extract groups.CONCLUSIONS. Camellia japonica extracts promoted antioxidative protein expression and suppressed apoptosis in HCE cells. Furthermore, CJ extracts improved clinical signs of dry eye and reduced oxidative stress and the expression of inflammatory markers, suggesting that eye drops containing CJ extract could be used as an adjunctive treatment for dry eye.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Inflammatory and Antioxidative Effects of Camellia japonica on Human Corneal Epithelial Cells and Experimental Dry Eye: In Vivo and In Vitro Study

Lee

Choi

Cui

et al. 2017

Invest. Ophthalmol. Vis. Sci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…A retrospective study of 40 patients found that symptoms and TBUT returned to baseline faster in CsA emulsion-treated eyes (4 vs 8 weeks), but did not find differences in refractive outcomes [55]. On the other hand, a prospective study of 21 patients found no significant differences in dry eye symptoms or tear parameters, but slightly better refractive outcomes in the CsA emulsion-treated group (higher frequency of patients within 0.5 D (Diopters) of intended correction at 3 months) [56].…”

Section: Human Studies Of Csa For Dry Eyementioning

confidence: 99%

“…Studies evaluating CsA use after refractive surgery showed faster symptom improvement and slightly better refractive outcomes [55,56]. In contact lens associated dry eye, CsA improved symptoms and temporal conjunctival staining in one study and had no effect over artificial tears in the other [57,58].…”

mentioning

confidence: 99%

Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence

Ames

2015

Clinical Investigation

View full text Add to dashboard Cite

Dry eye has gained recognition as a public health problem given its high prevalence, morbidity and cost implications. Although dry eye is common and affects patients’ quality of life, only one medication, cyclosporine 0.05% emulsion, has been approved by the US FDA for its treatment. In this review, we summarize the basic science and clinical data regarding the use of cyclosporine in the treatment of dry eye. Randomized controlled trials showed that cyclosporine emulsion outperformed vehicles in the majority of trials, consistently decreasing corneal staining and increasing Schirmer scores. Symptom improvement was more variable, however, with ocular dryness shown to be the most consistently improved symptom over vehicle.

show abstract

“…After 12 months or more of CsA treatment, 5/82 (6.1%) eyes continued to have signs or symptoms of dry eye. Lee et al73 performed a retrospective, nonrandomized comparative analysis in 40 patients who underwent myopic laser epithelial keratomileusis and were treated with CsA 0.05% plus the conventional regimen of moxifloxacin 0.5%, fluorometholone 0.1%, and preservative-free sodium hyaluronate 0.1% qid; and 20 patients who received the conventional regimen alone. The CsA group had less ocular discomfort by 4 weeks postoperatively, especially those with preoperative dry eye.…”

Section: Resultsmentioning

confidence: 99%

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature

Rhee¹,

Mah

2017

OPTH

View full text Add to dashboard Cite

To review the literature on the efficacy of cyclosporine (CsA) ophthalmic emulsion 0.05% on symptomatic relief in chronic dry eye disease. There is consistent evidence of objective improvements in chronic dry eye disease (Schirmer score, corneal and interpalpebral dye staining, and tear breakup time) with CsA, but variable results with symptomatic improvement, possibly due to patient tolerance of CsA, similar comforting effect with artificial tears and CsA vehicle, and the inherent subjective nature of symptom monitoring and analysis. This review explores the literature on CsA with special attention to symptomatic relief.

show abstract

Clinical Effectiveness of Topical Cyclosporine A 0.05% After Laser Epithelial Keratomileusis

Abstract: Treatment with topical cyclosporine A 0.05% can improve ocular discomfort and increase tear film BUT during the early postoperative period, especially in patients with preoperative dry eye.

Cited by 9 publications

References 32 publications

Anti-Inflammatory and Antioxidative Effects of Camellia japonica on Human Corneal Epithelial Cells and Experimental Dry Eye: In Vivo and In Vitro Study

Anti-Inflammatory and Antioxidative Effects of Camellia japonica on Human Corneal Epithelial Cells and Experimental Dry Eye: In Vivo and In Vitro Study

Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature

Contact Info

Product

Resources

About